The JE (Japanese Encephalitis) vaccine market is anticipated to grow at a CAGR of 5.20% during the forecast period of 2025-2034 driven by the increasing mosquito nuisance, raising awareness, and the growing investment in the healthcare sector by the governments across the 8 major markets.
Base Year
Historical Period
Forecast Period
The increasing frequency of government-led immunisation campaigns and public health initiatives is expected to drive the widespread adoption of JE vaccines, significantly boosting market demand and expansion in endemic regions.
Advancements in vaccine research, coupled with rising investments in vector surveillance and diagnostics, will enhance JE outbreak preparedness, accelerating vaccine development and market penetration in high-risk countries.
Growing collaborations between global health organisations, vaccine manufacturers, and governments will strengthen supply chain efficiency, ensuring stable vaccine availability and fostering long-term market sustainability for JE immunisation programmes.
Value in
2025-2034
JE (Japanese Encephalitis) Vaccine Market Outlook
*this image is indicative*
The Japanese encephalitis (JE) vaccine protects against the Japanese encephalitis virus, a mosquito-borne disease causing severe neurological complications, high fatality rates, and long-term disabilities. JE primarily affects children in endemic regions across Asia and the Western Pacific. Vaccination is the most effective preventive measure, with several inactivated and live-attenuated vaccine options available. WHO-prequalified JE vaccines ensure global accessibility, supporting mass immunisation programmes. Rising government initiatives, improved vaccine distribution, and growing awareness are driving market expansion, ensuring protection against JE and reducing the disease burden in high-risk populations.
Increased Research Investments to Boost Market Growth
The growing threat of JEV outbreaks and its impact on public and animal health is driving increased investments in research and vaccine development. Rising concerns about JEV transmission through mosquitos and swine populations have also prompted governments and research institutions to enhance surveillance, diagnostic capabilities, and vaccine innovations. For instance, in December 2024, the Swine Health Information Center (SHIC) and the Foundation for Food & Agriculture Research (FFAR) allocated USD 1.3 million to fund six new projects aimed at improving JEV prevention, preparedness, and response in the United States. These projects focus on transmission studies, vector identification, wildlife involvement, diagnostics, and vaccine development. Increased research efforts will likely accelerate vaccine advancements, enhance outbreak preparedness, and drive market growth in the coming years.
Government-Led Immunisation Programmes to Drive Japanese Encephalitis (JE) Vaccine Market Demand
Rising government initiatives to combat vector-borne diseases and the integration of Japanese Encephalitis vaccines into immunisation programmes are key market drivers. For instance, in July 2024, the Telangana Health Department launched a JE vaccination campaign across four districts, targeting 15.04 lakh children aged 9 months to 15 years. The programme aims to curb JE transmission by vaccinating school children and those in Anganwadi centres and healthcare facilities. By expanding vaccine accessibility, such large-scale campaigns will increase demand for JE vaccines, encourage further procurement, and drive market expansion. This initiative highlights the growing role of government-led immunisation efforts in reducing JE cases, improving vaccine adoption, and supporting overall market growth in the forecast period.
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
JE (Japanese Encephalitis) Vaccine Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
Market Breakup by Dose Type
Market Breakup by Age Group
Market Breakup by Distribution Channel
Market Breakup by Region
Vero Cell-Derived Vaccine to Lead the Segmentation by Type
The Vero cell-derived vaccine is poised to lead the market due to its high immunogenicity, long-lasting protection, and established safety profile. Governments and health organisations increasingly prefer this type for large-scale immunisation campaigns, especially in endemic regions. Rising investments in vaccine research and advancements in cell culture technology further drive its adoption. Additionally, WHO's prequalification of Vero cell-derived vaccines ensures broader global distribution, strengthening their market position. With increasing demand for effective JE prevention strategies, this segment is expected to contribute significantly to market expansion in the forecast period.
Multi-Dose Vaccine to Lead the Segmentation by Dose Type
The multi-dose vaccine segment is expected to dominate the JE (Japanese Encephalitis) vaccine market, primarily due to its cost-effectiveness and suitability for mass vaccination programmes. Government-led immunisation campaigns and routine childhood vaccination schedules in endemic regions favour multi-dose regimens, ensuring broader population coverage. Additionally, healthcare providers prefer multi-dose vials as they reduce logistical challenges and enhance vaccine storage efficiency. Rising public health awareness and increasing JE outbreaks further propel demand. As large-scale immunisation initiatives continue to expand, particularly in Asia-Pacific, this segment is set to significantly drive market growth in the coming years.
Pediatric Segment to Lead the JE (Japanese Encephalitis) Vaccine Market Segmentation by Age Group
The pediatric segment is projected to hold the largest market share, as children under 15 years old are most vulnerable to infection. High incidence rates among children in endemic regions necessitate large-scale paediatric immunisation programmes. Government initiatives, WHO recommendations and school-based vaccination drives further strengthen this segment. Increasing research into paediatric vaccine efficacy and the inclusion of JE vaccines in national immunisation schedules enhance accessibility. With a rising focus on preventing neurological complications and fatalities in young populations, the paediatric segment is expected to be a key driver of market growth.
Government Suppliers to Dominate the Segment by Distribution Channel
The government suppliers segment is anticipated to lead the JE (Japanese Encephalitis) vaccine market, as national immunisation programmes and global health organisations heavily procure vaccines for mass distribution. WHO, UNICEF and Gavi play crucial roles in supplying JE vaccines to endemic regions, ensuring widespread coverage. Additionally, government partnerships with pharmaceutical firms and vaccine manufacturers help stabilise supply chains. Subsidised vaccine programmes and bulk procurement strategies further strengthen this segment’s dominance. As public health authorities continue prioritising JE prevention, government suppliers will play a pivotal role in market expansion, ensuring equitable access to JE vaccines worldwide.
The Asia-Pacific region, particularly India and Japan, is poised to dominate the market due to high disease prevalence, large at-risk populations, and extensive government-led immunisation programmes. Countries like India, with strong government support and routine immunisation drives, significantly contribute to market expansion. Japan, a leader in vaccine innovation, ensures continuous advancements in JE vaccine development. Additionally, WHO and UNICEF initiatives focus on expanding vaccination coverage in endemic areas. With increasing awareness, rising healthcare expenditure, and growing collaborations between public and private sectors, the Asia-Pacific region will continue driving market growth throughout the forecast period.
The key features of the market report comprise clinical trials analysis, patent analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Valneva SE, a France-based biotechnology company headquartered in Saint-Herblain, was established in 2013. It specialises in developing and commercialising innovative vaccines for infectious diseases. Valneva is a key player in the Japanese Encephalitis (JE) vaccine market with its IXIARO® vaccine , a Vero cell-derived inactivated vaccine approved for travellers and military personnel. The company focuses on research-driven advancements and strong partnerships with global health organisations, ensuring high vaccine efficacy and accessibility. With a robust pipeline, Valneva continues to enhance JE immunisation efforts worldwide.
Bharat Biotech, headquartered in Hyderabad, India, was founded in 1996 and is a leading vaccine manufacturer. It has played a crucial role in controlling Japanese Encephalitis (JE) with JENVAC®, a WHO-prequalified inactivated Vero cell-derived vaccine. Bharat Biotech supplies JE vaccines to national immunisation programmes and global markets, ensuring broad accessibility. The company emphasises research, innovation, and large-scale production to meet the growing vaccine demand. With a strong global presence, Bharat Biotech remains a key driver in JE prevention and immunisation efforts.
SK bioscience, a South Korean biopharmaceutical company, was established in 2018 and is headquartered in Seongnam, South Korea. It specialises in developing next-generation vaccines, including those for Japanese Encephalitis (JE). The company focuses on advanced biotechnologies and strategic partnerships to enhance vaccine accessibility. SK bioscience has contributed to JE immunisation programmes, ensuring high-quality vaccines for endemic regions. With continuous investment in research and global collaborations, it aims to strengthen its JE vaccine portfolio and expand its market reach in the coming years.
Zuellig Pharma, headquartered in Hong Kong, was founded in 1922 and is a leading healthcare services provider in Asia. It plays a vital role in the Japanese Encephalitis (JE) vaccine market by distributing vaccines across high-risk regions through its extensive logistics network. Zuellig Pharma partners with vaccine manufacturers to ensure efficient supply chain management, supporting immunisation efforts in Southeast Asia and beyond. With expertise in pharmaceutical distribution and healthcare solutions, the company strengthens JE vaccine accessibility, making it a key contributor to global vaccination initiatives.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include Substipharm Biologics, Meiji Holdings Co., Ltd., Chengdu Institute of Biological Products, Sanofi, and Acambis plc.
India Disposable Medical Gloves Market
Latin America In-vitro Diagnostics Market
Global Implantable Medical Devices Market
Latin America Advanced Wound Care Market
Global Aortic Valve Replacement Devices Market
Global Acute Kidney Injury Treatment Market
North America Laboratory Informatics Market
Global Laboratory Information System Market
South Africa Orthopaedic Braces and Supports Market
Health Economics and Outcomes Research (HEOR) Market
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2024 |
| Historical Period | 2018-2024 |
| Forecast Period | 2025-2034 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Dose Type |
|
| Breakup by Age Group |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share